CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).-MedSci.cn

CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).

Abramson, JS; Palomba, ML; Gordon, LI; Lunning, MA; Arnason, JE; Forero-Torres, A; Wang, M; Albertson, TM; Allen, T; Sutherland, C; Xie, BH; Garcia, J; Siddiqi, T

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务